Agalsidase alfa is an intravenous enzyme replacement therapy for patients with Fabry disease.1 The mechanism of action of agalsidase alfa is presented in Figure 1. The availability of agalsidase alfa differs between countries. For further information, please consult your local prescribing information.
Mechanism of action of agalsidase alfa.1,2
C-ANPROM/INT/FAB/0017; Date of preparation: March 2021
- Shire Pharmaceuticals Ltd. Replagal® EU Summary of Product Characteristics. Last updated November 2020.
- Ferraz MJ, Kallemeijn WW, Mirzaian M, et al. Gaucher disease and Fabry disease: new markers and insights in pathophysiology for two distinct glycosphingolipidoses. Biochim Biophys Acta 2014; 1841: 811-825.